<?xml version='1.0' encoding='utf-8'?>
<document id="30443705"><sentence text="Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers."><entity charOffset="41-51" id="DDI-PubMed.30443705.s1.e0" text="nitisinone" /></sentence><sentence text="Nitisinone inhibits the cytochrome P450 (CYP) subfamilies CYP2C9, CYP2D6, and CYP2E1 and the organic anion transporter (OAT) isoforms OAT1 and OAT3 in vitro"><entity charOffset="0-10" id="DDI-PubMed.30443705.s2.e0" text="Nitisinone" /></sentence><sentence text=" Since the effect of nitisinone on these enzymes and transporters in humans is still unknown, the purpose of this study was to evaluate the effect of nitisinone on these CYP subfamilies and OAT isoforms"><entity charOffset="21-31" id="DDI-PubMed.30443705.s3.e0" text="nitisinone" /><entity charOffset="150-160" id="DDI-PubMed.30443705.s3.e1" text="nitisinone" /><pair ddi="false" e1="DDI-PubMed.30443705.s3.e0" e2="DDI-PubMed.30443705.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30443705.s3.e0" e2="DDI-PubMed.30443705.s3.e1" /></sentence><sentence text="" /><sentence text="This was an open-label, nonrandomized, two-arm, phase 1 study (EudraCT: 2016-004297-17) in healthy volunteers" /><sentence text=" The substrates (tolbutamide, metoprolol, and chlorzoxazone for the respective CYPs and furosemide for the OATs) were administered as single doses, before and after 15 days of once daily dosing of 80 mg nitisinone, to determine the AUC∞ ratios ([substrate+nitisinone]/[substrate])"><entity charOffset="17-28" id="DDI-PubMed.30443705.s6.e0" text="tolbutamide" /><entity charOffset="30-40" id="DDI-PubMed.30443705.s6.e1" text="metoprolol" /><entity charOffset="46-59" id="DDI-PubMed.30443705.s6.e2" text="chlorzoxazone" /><entity charOffset="88-98" id="DDI-PubMed.30443705.s6.e3" text="furosemide" /><entity charOffset="203-213" id="DDI-PubMed.30443705.s6.e4" text="nitisinone" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e0" e2="DDI-PubMed.30443705.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e0" e2="DDI-PubMed.30443705.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e0" e2="DDI-PubMed.30443705.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e0" e2="DDI-PubMed.30443705.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e0" e2="DDI-PubMed.30443705.s6.e4" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e1" e2="DDI-PubMed.30443705.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e1" e2="DDI-PubMed.30443705.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e1" e2="DDI-PubMed.30443705.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e1" e2="DDI-PubMed.30443705.s6.e4" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e2" e2="DDI-PubMed.30443705.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e2" e2="DDI-PubMed.30443705.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e2" e2="DDI-PubMed.30443705.s6.e4" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e3" e2="DDI-PubMed.30443705.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30443705.s6.e3" e2="DDI-PubMed.30443705.s6.e4" /></sentence><sentence text=" Nitisinone pharmacokinetics, safety, and tolerability were also assessed, and blood and urine were collected to determine substrate and nitisinone concentrations by LC-MS/MS"><entity charOffset="1-11" id="DDI-PubMed.30443705.s7.e0" text="Nitisinone" /><entity charOffset="137-147" id="DDI-PubMed.30443705.s7.e1" text="nitisinone" /><pair ddi="false" e1="DDI-PubMed.30443705.s7.e0" e2="DDI-PubMed.30443705.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30443705.s7.e0" e2="DDI-PubMed.30443705.s7.e1" /></sentence><sentence text="" /><sentence text="Thirty-six subjects were enrolled with 18 subjects included in each arm" /><sentence text=" The least square mean ratio (90% confidence interval) for AUC∞ was 2" /><sentence text="31 (2" /><sentence text="11-2" /><sentence text="53) for tolbutamide, 0"><entity charOffset="8-19" id="DDI-PubMed.30443705.s13.e0" text="tolbutamide" /></sentence><sentence text="95 (0" /><sentence text="88-1" /><sentence text="03) for metoprolol, 0"><entity charOffset="8-18" id="DDI-PubMed.30443705.s16.e0" text="metoprolol" /></sentence><sentence text="73 (0" /><sentence text="67-0" /><sentence text="80) for chlorzoxazone, and 1"><entity charOffset="8-21" id="DDI-PubMed.30443705.s19.e0" text="chlorzoxazone" /></sentence><sentence text="72 (1" /><sentence text="63-1" /><sentence text="81) for furosemide"><entity charOffset="8-18" id="DDI-PubMed.30443705.s22.e0" text="furosemide" /></sentence><sentence text=" Clinically relevant nitisinone steady-state concentrations were reached after 12 days: mean Cav,ss of 94"><entity charOffset="21-31" id="DDI-PubMed.30443705.s23.e0" text="nitisinone" /></sentence><sentence text="08 μM" /><sentence text=" All treatments were well tolerated, and no safety concerns were identified" /><sentence text="" /><sentence text="Nitisinone did not affect CYP2D6 activity, was a weak inducer of CYP2E1, and was a weak inhibitor of OAT1 and OAT3"><entity charOffset="0-10" id="DDI-PubMed.30443705.s27.e0" text="Nitisinone" /></sentence><sentence text=" Nitisinone was a moderate inhibitor of CYP2C9, and treatment may therefore result in increased plasma concentrations of comedications metabolized primarily via this enzyme"><entity charOffset="1-11" id="DDI-PubMed.30443705.s28.e0" text="Nitisinone" /></sentence><sentence text="" /><sentence text="EudraCT 2016-004297-17" /><sentence text="" /></document>